SCHEMBL3316478

SCHEMBL3316478

C=CCc1occc(=O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
APP P05067 6/20 0.37
GABRA1 P14867 3/20 0.35
GABRB2 P47870 3/20 0.35
SRD5A1 P18405 2/20 0.35
FTO Q9C0B1 1/20 0.33
MAPK1 P28482 1/20 0.33
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP12 P39900 1/20 0.33
MMP13 P45452 1/20 0.33
XDH P47989 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
ALDH2 P05091 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6998427 0.76 KDM4E (0.52) KDM4ELMNAAPPFTOMAPK1
SCHEMBL5642283 0.76
SCHEMBL10902278 0.75 KDM4E (0.43) KDM4ELMNAAPP
SCHEMBL25948708 0.75 KDM4E (0.43) KDM4ELMNAAPP
SCHEMBL561713 0.75 KDM4E (0.50) KDM4ELMNAAPPFTOMAPK1
E637 SCHEMBL41817 0.75 KDM4E (0.55) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL1870685 0.75 KDM4E (0.55) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL6657728 0.73 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL8026696 0.73 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
SCHEMBL9700110 0.73 KDM4E (0.48) KDM4ELMNAAPPFTOMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US claimed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP claimed
CN-118660702-A Antimicrobial compositions 生物活性协同有限公司 2024-09-17 CN claimed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO claimed
WO-1989009211-A1 PROCESS FOR PRODUCING PYRID-4-ONES THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-05 WO claimed
EP-0335745-A1 Process for producing pyrid-4-ones THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-04 EP claimed
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US disclosed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP disclosed
CN-118660702-A Antimicrobial compositions 生物活性协同有限公司 2024-09-17 CN disclosed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO disclosed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO disclosed
EP-3192793-B1 COMPOSITIONS CONTAINING IRON HYDROXYPYRONE SHIELD TX UK LTD (GB) 2022-03-16 EP disclosed
EP-3116548-B1 COMPOSITION SHIELD TX UK LTD (GB) 2021-02-17 EP disclosed
EP-1506183-A1 METHOD OF FORMING IRON HYDROXYPYRONE COMPOUNDS Vitra Pharmaceuticals Ltd. (GB) 2005-02-16 EP disclosed
WO-2003097627-A1 METHOD OF FORMING IRON HYDROXYPYRONE COMPOUNDS VITRA PHARMACEUTICALS LIMITED (GB) 2003-11-27 WO disclosed
US-6339080-B1 FOR THERAPY AND PROPHYLAXIS OF IRON DEFICIENCY DISORDERS INCLUDING IRON DEFICIENCY ANAEMIA VITRA PHARMACEUTICALS LTD. (GB) 2002-01-15 US disclosed
WO-1989009211-A1 PROCESS FOR PRODUCING PYRID-4-ONES THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-05 WO disclosed
EP-0335745-A1 Process for producing pyrid-4-ones THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-04 EP disclosed
US-4608367-A γ-Pyrone phosphoric ester derivatives and insecticidal and miticidal compositions thereof OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1986-08-26 US disclosed
US-4246178-A CHEMICAL INTERMEDIATE FOR THE FLAVOR MALTOL SHIN-ETSU CHEMICAL CO., LTD. (JP) 1981-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS NOD2, PYCARD, CLPP KDM4E 4332/4885LMNA 2204/4885APP 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.